Functional genomic landscape of cancer-intrinsic evasion of killing by T cells

Immunotherapy

Targeting T Cell Metabolism for Improvement of Cancer Immunotherapy

Front Oncol.

Le Bourgeois T, Strauss L, Aksoylar HI, Daneshmandi S, Seth P, Patsoukis N, Boussiotis VA

doi: 10.3389/fonc.2018.00237.

T Cells

Engineering CAR-T Cells for Improved Function Against Solid Tumors

Front Immunol.

Morgan MA, Schambach A

doi: 10.3389/fimmu.2018.02493.

T Cells

Counter-regulation of regulatory T cells by autoreactive CD8+ T cells in rheumatoid arthritis

doi: 10.1016/j.jaut.2019.02.001.

T Cells

Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Anti-Tumor T-cell Immunity

Cancer Discov

Hong A, Piva M, Liu S, Hugo W, Lomeli SH, Zoete V, Randolph CE, Yang Z, Wang Y, Lee JJ, Lo SJ, Sun L, Vega-Crespo A, Garcia AJ, Shackelford DB, Dubinett SM, Scumpia PO, Byrum SD, Tackett AJ, Donahue TR, Michielin O, Holmen SL, Ribas A, Moriceau G, Lo RS

doi: 10.1158/2159-8290.CD-20-0873

Selective T-cell depletion targeting CD45RA reduces viremia and enhances early T-cell recovery compared to CD3-targeted T-cell depletion

Transpl Infect Dis.

Triplett BM, Muller B, Kang G, Ying L, Cross SJ, Moen J, Cunningham L, Janssen W, Mamcarz E, Shook DR, Srinivasan A, Choi J, Hayden RT, Leung W

doi: 10.1111/tid.12823.

ImmunotherapyT Cells

Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells

J Autoimmun.

Alissafi T, Hatzioannou A, Legaki AI, Varveri A, Verginis P

doi: 10.1016/j.jaut.2019.102310.

ImmunotherapyT Cells

Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology

Front Immunol.

Mylvaganam G, Yanez AG, Maus M, Walker BD

doi: 10.3389/fimmu.2019.02109.

Immunotherapy

Reprogramming T-cells for adoptive immunotherapy of ovarian cancer

Expert Opin Biol Ther.

Genta S, Ghisoni E, Giannone G, Mittica G, Valabrega G

T Cells

Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies

Lancet

Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar OC, Lucchini G, Pinner D, Jain N, Kantarjian H, Boissel N, Maus MV, Frigault MJ, Baruchel A, Mohty M, Gianella-Borradori A, Binlich F, Balandraud S, Vitry F, Thomas E, Philippe A, Fouliard S, Dupouy S, Marchiq I, Almena-Carrasco M, Ferry N, Arnould S, Konto C, Veys P, Qasim W, UCART19 Group.

doi: 10.1016/S0140-6736(20)32334-5

Related content

Targeting T Cell Metabolism for Improvement of Cancer Immunotherapy

Engineering CAR-T Cells for Improved Function Against Solid Tumors

Counter-regulation of regulatory T cells by autoreactive CD8+ T cells in rheumatoid arthritis

Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Anti-Tumor T-cell Immunity

Selective T-cell depletion targeting CD45RA reduces viremia and enhances early T-cell recovery compared to CD3-targeted T-cell depletion

Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells

Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology

Reprogramming T-cells for adoptive immunotherapy of ovarian cancer

Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies